首页> 美国卫生研究院文献>PLoS Clinical Trials >KPU-300, a Novel Benzophenone–Diketopiperazine–Type Anti-Microtubule Agent with a 2-Pyridyl Structure, Is a Potent Radiosensitizer That Synchronizes the Cell Cycle in Early M Phase
【2h】

KPU-300, a Novel Benzophenone–Diketopiperazine–Type Anti-Microtubule Agent with a 2-Pyridyl Structure, Is a Potent Radiosensitizer That Synchronizes the Cell Cycle in Early M Phase

机译:KPU-300是具有2-吡啶基结构的新型苯甲酮-二酮哌嗪类抗微管剂,是一种有效的放射增敏剂,可在M期早期同步细胞周期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

KPU-300 is a novel colchicine-type anti-microtubule agent derived from plinabulin (NPI-2358). We characterized the effects of KPU-300 on cell cycle kinetics and radiosensitization using HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci). Cells treated with 30 nM KPU-300 for 24 h were efficiently synchronized in M phase and contained clearly detectable abnormal Fucci fluorescence. Two-dimensional flow-cytometric analysis revealed a fraction of cells distinct from the normal Fucci fluorescence pattern. Most of these cells were positive for an M phase marker, the phosphorylated form of histone H3. Cells growing in spheroids responded similarly to the drug, and the inner quiescent fraction also responded after recruitment to the growth fraction. When such drug-treated cells were irradiated in monolayer, a remarkable radiosensitization was observed. To determine whether this radiosensitization was truly due to the synchronization in M phase, we compared the radiosensitivity of cells synchronized by KPU-300 treatment and cells in early M phase isolated by a combined method that took advantage of shake-off and the properties of the Fucci system. Following normalization against the surviving fraction of cells treated with KPU-300 alone, the surviving fractions of cells irradiated in early M phase coincided. Taken together with potential vascular disrupting function in vivo, we propose a novel radiosensitizing strategy using KPU-300.
机译:KPU-300是一种新的秋水仙碱类抗微管药,衍生自纤毛蛋白(NPI-2358)。我们使用表达基于荧光泛素化的细胞周期指示剂(Fucci)的HeLa细胞表征了KPU-300对细胞周期动力学和放射增敏的影响。用30 nM KPU-300处理24 h的细胞在M相中有效同步,并包含清晰可检测的异常Fucci荧光。二维流式细胞仪分析揭示了一部分细胞不同于正常的Fucci荧光模式。这些细胞大多数对M相标记(组蛋白H3的磷酸化形式)呈阳性。球形中生长的细胞对药物的反应相似,内部静止部分在募集到生长部分后也有反应。当将这种药物处理的细胞单层照射时,观察到显着的放射增敏作用。为了确定这种放射增敏作用是否确实是由于M期的同步引起的,我们比较了通过KPU-300处理同步化的细胞与利用结合法分离和结合的特性分离的M期早期细胞的放射敏感性。 Fucci系统。针对仅用KPU-300处理的细胞的存活分数进行归一化后,在早期M期照射的细胞的存活分数重合。结合体内潜在的血管破坏功能,我们提出了一种使用KPU-300的新型放射增敏策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号